                         SEQUENCE LISTING

<110>  Midatech Limited
       University College Cardiff Consultants Limited
       NanoPass Technologies Ltd.
       Leiden University Medical Center
       Institut National de la Sante et de la Recherche Medicale
 
<120>  Nanoparticle - Based Antigen Specific Immunotherapy

<130>  CSC/BP7190267

<150>  GB 1506112.0
<151>  2015-04-10

<160>  12    

<170>  PatentIn version 3.3

<210>  1
<211>  18
<212>  PRT
<213>  Homo sapiens

<400>  1

Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly 
1               5                   10                  15      


Ile Val 
        


<210>  2
<211>  14
<212>  PRT
<213>  Homo sapiens

<400>  2

Thr Val Tyr Gly Ala Phe Asp Pro Leu Leu Ala Val Ala Asp 
1               5                   10                  


<210>  3
<211>  10
<212>  PRT
<213>  Mus musculus

<400>  3

Tyr Val Arg Pro Leu Trp Val Arg Met Glu 
1               5                   10  


<210>  4
<211>  14
<212>  PRT
<213>  Mus musculus

<400>  4

Trp Ser Arg Met Asp Gln Leu Ala Lys Glu Leu Thr Ala Glu 
1               5                   10                  


<210>  5
<211>  15
<212>  PRT
<213>  Mus musculus

<400>  5

Ser His Leu Val Glu Ala Leu Tyr Leu Val Ser Gly Glu Arg Gly 
1               5                   10                  15  


<210>  6
<211>  14
<212>  PRT
<213>  Homo sapiens

<400>  6

Trp Ser Lys Met Asp Gln Leu Ala Lys Glu Leu Thr Ala Glu 
1               5                   10                  


<210>  7
<211>  110
<212>  PRT
<213>  Homo sapiens

<400>  7

Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu 
1               5                   10                  15      


Trp Gly Pro Asp Pro Ala Ala Ala Phe Val Asn Gln His Leu Cys Gly 
            20                  25                  30          


Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu Arg Gly Phe 
        35                  40                  45              


Phe Tyr Thr Pro Lys Thr Arg Arg Glu Ala Glu Asp Leu Gln Val Gly 
    50                  55                  60                  


Gln Val Glu Leu Gly Gly Gly Pro Gly Ala Gly Ser Leu Gln Pro Leu 
65                  70                  75                  80  


Ala Leu Glu Gly Ser Leu Gln Lys Arg Gly Ile Val Glu Gln Cys Cys 
                85                  90                  95      


Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn 
            100                 105                 110 


<210>  8
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Murine peptide with linker at the N-terminus

<400>  8

Ala Ala Tyr Trp Ser Arg Met Asp Gln Leu Ala Lys Glu Leu Thr Ala 
1               5                   10                  15      


Glu 
    


<210>  9
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Murine peptide with linker at the N-terminus

<400>  9

Ala Ala Tyr Tyr Val Arg Pro Leu Trp Val Arg Met Glu 
1               5                   10              


<210>  10
<211>  18
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Murine peptide with linker at the N-terminus

<400>  10

Ala Ala Tyr Ser His Leu Val Glu Ala Leu Tyr Leu Val Ser Gly Glu 
1               5                   10                  15      


Arg Gly 
        


<210>  11
<211>  17
<212>  PRT
<213>  Gallus gallus

<400>  11

Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly 
1               5                   10                  15      


Arg 
    


<210>  12
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Artifically created hybrid peptide

<400>  12

Asp Leu Gln Thr Leu Ala Leu Trp Ser Arg Met Asp 
1               5                   10          


